Entinostat (MS-275)

製品コードS1053 別名:SNDX-275

Entinostat (MS-275)化学構造

分子量(MW):376.41

Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.

サイズ 価格(税別)  
JPY 15106.00
JPY 11620.00
JPY 24900.00
JPY 44820.00
JPY 127820.00

文献中Selleckの製品使用例(63)

カスタマーフィードバック(14)

  • (A) U87 cells were cultured in the presence of DMSO, 1 uM MS-275 alone, 100 ng/ml IFN-λ1 alone, or both for the course of 4 d. Cell numbers were manually determined by hemacytometer counting at the indicated time points. (B, F) Cell proliferation of U87 cells or U87 spheroids in 3D culture with indicated treatment were performed using the WST-1 assay, which measures active cellular metabolism. (C) U87 spheroid formation in 3D culture was photographed at day 14 in culture (representative images are shown; 200x magnification). (D-E) Quantification of the relative sizes and numbers of U87 spheroids in (C). (G) Cell cycle analysis was performed in U87 cells with indicated treatment using propidium iodide staining. Numbers in the histogram show fractions (percent) of sub-G1, N, 2N, and polyploidy from left to right. (H) U87 cells with indicated treatment were stained with Annexin V-FITC and 7-AAD. Numbers indicate the percentage of FITC-positive cells (upper left quadrant). FITC, fluorescein isothiocyanate; 7-AAD, 7-Aminoactinomycin. In all panels, data represent the mean and SEM of at least three experiments.

    PLoS Biol 2014 12, e1001758. Entinostat (MS-275) purchased from Selleck.

    Inhibition of HDAC1-mediated DNMT1 deacetylation promotes DNMT1 proteasomal degradation. (A) Knockout of HAUSP potentiates HDAC inhibitor (HDACi)-induced DNMT1 degradation. Parental or HAUSP KO DLD1 cells were treated or not with 5 μM HDACi MS-275 for 72 hours and cell lysates were blotted with the indicated antibodies. (B) HDAC inhibition induces DNMT1 ubiquitination. HAUSP WT or KO cells were treated with or without HDACi for 24 hours and MG132 for 12 hours before being harvested to make cell lysates. DNMT1 immunoprecipitates were blotted with an antibody against ubiquitin. Because the abundance of DNMT1 in the HAUSP KO cells is lower than in WT cells, more KO cells were used than WT cells to obtain equal amounts of precipitated DNMT1 proteins. (C) DNMT1 is acetylated after HDACi treatment. DNMT1 immunoprecipitates from cells treated with HDACi were blotted with an antibody against acetylated lysine (Ac-K). (D) A DNMT1 acetylation site mutant is resistant to HDACi-induced degradation. HEK 293 cells were transfected with WT DNMT1 or a DNMT1 mutant lacking four known acetylation sites (K173R, K1113R, K115R, and K117R) and treated with MS-275 for 48 hours and with CHX for 24 hours. Cell lysates were blotted with the indicated antibodies. (E) Knockdown of HDAC1 decreases the abundance of DNMT1. RKO cells were treated with the indicated concentration of doxycycline (Dox) for 48 hours to induce expression of an shRNA directed against HDAC1. Western blots were performed with the indicated antibodies. (F) Knockdown of HDAC1 leads to increased acetylation of DNMT1. RKO cells expressing an inducible HDAC1 shRNA were treated with or without Dox (4 mg/ml) for 36 hours and then with MG132 for 12 hours. DNMT1 immunoprecipitates were blotted with an antibody against Ac-K. Cell lysates were also blotted with antibodies against HDAC1 and b-actin.

     

     

    Sci Signal 2010 3, ra80. Entinostat (MS-275) purchased from Selleck.

  • The E3 ligase UHRF1 ubiquitinates DNMT1. (A) HDAC inhibition enhances DNMT1 interaction with UHRF1. HEK 293 cells were transfected with plasmids expressing Myc-DNMT1 and Flag-UHRF1 and treated with or without MS-275 for 24 hours. Myc-DNMT1 immunoprecipitates were blotted with the indicated antibodies. (B and C) HDAC inhibition enhances the interaction of endogenous DNMT1 and UHRF1. Cells were treated with or without MS-275 and UHRF1 (B) or DNMT1 (C) immunoprecipitates were blotted with the indicated antibodies. (D) UHRF1 ubiquitinates DNMT1. HEK 293 cells were transfected with the indicated plasmids. Antibodies against Myc immunoprecipitates were blotted with antibody against HA to detect ubiquitinated DNMT1. Myc-DNMT1D, DNMT1 mutant lacking the HAUSP-interacting domain. UHRF1DRING, UHRF1 with a RING domain deletion. (E) Knockdown of UHRF1 blocks HDACi-induced DNMT1 degradation. HEK 293 cells were transfected with control siRNA or siRNAs against UHRF1 and treated with or without MS-275. Western blotting was performed with the indicated antibodies. (F) Overexpression of UHRF1 leads to degradation of a DNMT1 mutant lacking the HAUSP-interacting domain (DNMT1D). Full-length DNMT1 or DNMT1D was cotransfected into HEK 293 cells with the indicated expression vectors. Cell lysates were blotted with the indicated antibodies. (G) DNMT1, HAUSP, UHRF1, HDAC1, and PCNA associate with Tip60. Flag-tagged Tip60 immunoprecipitates were blotted with the indicated antibodies.

     

     

    Sci Signal 2010 3, ra80. Entinostat (MS-275) purchased from Selleck.

    HAUSP KO cells are more sensitive to HDACi-induced apoptosis.(A) HDAC inhibition induces apoptosis in HAUSP KO cells.HAUSP WT or KO cells were treated with or without MS-275 at the indicated concentration for 72 hours, then fixed and stained with propidium iodide. Flow cytometric analyses were used to profile sub-G1, G1, and G2-M cell populations. Apoptotic cells were quantified after the indicated clones were treated with either 5 or 10 μM MS-275. The means and SDs of three independent experiments were plotted (*P<0.001, t test). (B) HDAC inhibition induces apoptosis in HAUSP KO cells but leads to G2-M arrest in WT cells.Cell cycle profiles of HAUSP WT or KOcells that were treated or not with 5 μM MS-275. (C)HDAC inhibition increases the abundance of apoptotic cell markers. The indicated cells were treated with or without MS-275 for 72 hours.Cell lysates were blotted with antibodies against cleaved caspase 3 and β-actin. (D) Ectopic overexpression of DNMT1 in HAUSP KO cells suppresses apoptosis. HAUSP KO clones or HAUSP KO cells inducibly

    overexpressingDNMT1 were treatedwith 10 μM MS-275. Apoptotic cell populations were quantified by fluorescence-activated cell sorting (FACS) analyses (*P < 0.001, t test). Cell lysates from these cells were blotted with the indicated antibodies. (E) HDAC inhibition arrests the growth of HAUSP KO cells. DLD1, HAUSP KO, and KO cells ectopically expressing HAUSP were treated with the indicated concentration of MS-275 for 4 days. Cell numbers were determined and data from eight replicates were plotted (**P <0.001, t test). (FandG) HDACi inhibits tumor xenograft formation ofHAUSP KOcells.Athymic nudemice (five in each group)were injectedsubcutaneously and bilaterallywith cells of the indicated genotypes. Mice were treated with or without MS-275 at 15mg/kg for 4 weeks. Tumors were harvested and photographed (F). Tumor sizes of the indicated groupsweremeasuredweekly and theaveragevolumes at each timepoint were plotted (G).MANOVA analyses were performed to determine whether there was an overall difference of the tumor sizes, as well as whether there was a difference in development over time of tumor sizes between the two groups (P < 0.0001).
     

     

    Sci Signal 2010 3, ra80. Entinostat (MS-275) purchased from Selleck.

  • Numerous APC (+) oligodendrocytes (middle upper panel) with ellipsoid nuclei labeled with Sytox (left upper panel) were observed in 8 week old Thy-1 mitoCFP control MONs. NF-200 (+) neurofilaments extended along the MON as linear individual fibers (right upper panel). A period of OGD (60 min) caused a significant loss of APC (+) oligodendrocytes, a gain in the appearance of pyknotic nuclei (dense, brighter nuclei, white arrows, OGD panel), and loss of NF-200 (+) axon structures, which were, replaced with axonal head and bulb formation (white asterisks). Pretreatment with SAHA (1uM) or MS-275 (1uM) effectively preserved APC (+) oligodendrocytes, together with numerous linear individual NF-200 (+) axons. Note fewer pyknotic nuclei (white arrows, SAHA and MS-275 panels) after OGD in MONs treated with SAHA or MS-275.

    J Neurosci 2011 31, 3990-9. Entinostat (MS-275) purchased from Selleck.

    Notch1ICD, Notch2ICD, and Notch3ICD were transduced into human aortic SMCs, which were then treated with HDAC inhibitors TSA or MS-275 or with vehicle DMSO (con). The top 2 rows are different exposures of the same blot to detect the epitope tags on the N ICD constructs. Longer (top row) and shorter ( second row) exposures are shown because t he level of N2ICD expression was lower than that of N1ICD and N3ICD. SMC markers were analyzed and were similarly induced by activation of each Notch r eceptor. Both TSA and MS-275 significantly suppressed the induction of SMC proteins by Notch activation.

    J Am Heart Assoc 2012 1, e000901. Entinostat (MS-275) purchased from Selleck.

  • LSD1 and HDAC inhibitors exhibit synergistic growth inhibition. Cells were simultaneously treated with pargyline or HDAC inhibitors for 48 h.

     

     

    Breast Cancer Res Treat 2012 131, 777-789. Entinostat (MS-275) purchased from Selleck.

    Histone acetylation in the spinal cord after HDACI treatment. Histone acetylation in the lumbar spinal cord of mice receiving i.t. SAHA (25 μg) or MS-275 (0.5 μg) for 30 min was analyzed by immunoblot (A, B) and immunofluorescent histochemistry (C) for antigens indicated. Animals receiving i.t. saline were used as control. Images of the H3K9/18ac signals in the left half of the lumbar spinal cord are shown in the first row in C. Immunosignals of indicated antigens in the superficial dorsal horn are presented in the rest rows in C.

    Mol Pain 2010 6, 51. Entinostat (MS-275) purchased from Selleck.

  • B. Confluent quiescent foreskin fibroblasts were treated with HDAC1 inhibitor or vehicle for 24 hours. Type I procollagen protein levels in whole cell lysates were determined by immunoblotting. A representative result of three independent experiments is shown. The band density was evaluated by densitometry. C. Under the same conditions, mRNA levels of the α1(I) collagen (COL1A1) gene were determined using reverse transcription quantitative real-time PCR. The graph represents -fold change in COL1A1 mRNA levels in comparison to unstimulated controls, which were arbitrarily set at 100. The mean and SD from three separate experiments are shown. * p<0.05 versus control cells treated with vehicle.

    PLoS One 2013 8, e74930. Entinostat (MS-275) purchased from Selleck.

    Inhibition of LSD1 activity by HDAC inhibitors. a MDA-MB-231 and MDA-MB-468 cells were exposed to indicated HDAC inhibitors for 24 h.

     

     

    Exp Dermatol 2010 19, 1096-1102. Entinostat (MS-275) purchased from Selleck.

  • HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h, and their expression of GRP78, PERK-eIF2α axis and ATF4, ATF3, CHOP and DR5 proteins.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Entinostat (MS-275) purchased from Selleck.

    HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h. ATF4, ATF3, CHOP and DR5 proteins were measured by Western blot.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Entinostat (MS-275) purchased from Selleck.

  •  

    HDAC inhibition increases SMN-luciferase reporter mRNA levels. qRT-PCR was used to measure increases of SMN-luciferase mRNA following treatment with HDAC inhibitors. Fold increase of mRNA was normalized to GAPDH.

    Biochem Bioph Res Co 2010 414, 25-30. Entinostat (MS-275) purchased from Selleck.

    Western blot analysis of Acetyl-H3 and H3. 0-20μM MS-275 was added.

     

     

    2011 Dr. Zhang of Tianjin Medical University. Entinostat (MS-275) purchased from Selleck.

製品安全説明書

HDAC阻害剤の選択性比較

生物活性

製品説明 Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.
ターゲット
HDAC1 [2]
(Cell-free assay)
HDAC3 [2]
(Cell-free assay)
0.51 μM 1.7 μM
体外試験

MS-275 shows inhibitory to HDACs by 2'-amino group. MS-275 induces accumulation of p21WAF1/CIP1 and gelsolin in K562 cell. MS-275 could reduce S-phase cells and induce G1-phase cells in A2780 cell. MS-275 inhibits the proliferation of human tumor cell lines including A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 with IC50 from 41.5 nM to 4.71 μM, which due to HAD-inhibition. [1] MS-275 is not sensitive to other HDACs (4, 6, 8 and 10) with IC50 about/above 100 μM. [2] MS-275 shows great inhibition to human leukemia and lymphoma cells, including U937, HL-60, K562, and Jurkat. MS-275 also decreases expression of cyclin D1 and the antiapoptotic proteins Mcl-1 and XIAP. [3]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SCC-3 NX7XcZloT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37IOWlEPTB;MD6wOlEh|ryP NUjOUY0xW0GQR1XS
ALL-PO NYGyNlM3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjzTWM2OD1yLkC2N|U2KM7:TR?= MX\TRW5ITVJ?
697 MleyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoD2TWM2OD1yLkC5PVc3KM7:TR?= M36ybXNCVkeHUh?=
NCI-H748 NVjPPY5uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDXUXdKSzVyPUCuNVA{OzRizszN MVjTRW5ITVJ?
NKM-1 M4XH[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDXTWM2OD1yLkGwPVEzKM7:TR?= M{jPcHNCVkeHUh?=
ES1 NV;WcYh{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXWXm9KSzVyPUCuNVEzPTVizszN MmXtV2FPT0WU
NCI-H1963 NYrBd4FlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;KTWM2OD1yLkGxOVc6KM7:TR?= NU\TO3R3W0GQR1XS
NCI-H1417 NWKyc|hyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTBwMUK5O|Qh|ryP NGjIZpNUSU6JRWK=
NEC8 NGG5O3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4joN2lEPTB;MD6xN|UzPyEQvF2= M1HoWXNCVkeHUh?=
CRO-AP2 M{nFZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFmzZ|FKSzVyPUCuNVY5QDlizszN MVTTRW5ITVJ?
A3-KAW M{\PfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGi5SpJKSzVyPUCuNVc3OjdizszN NVW0V3VRW0GQR1XS
SF539 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\BVmlEPTB;MD6xPVU6OyEQvF2= MXTTRW5ITVJ?
NOS-1 M37sWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTBwMUm2NVkh|ryP NIHNT3NUSU6JRWK=
NTERA-S-cl-D1 NXWwbmhFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTBwMkCxNVMh|ryP NWH3[2VxW0GQR1XS
COR-L88 MkL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTBwMkK5OVkh|ryP MY\TRW5ITVJ?
EM-2 NWHBRnROT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVn4e5NFUUN3ME2wMlI1ODd7IN88US=> NUHERZNWW0GQR1XS
KARPAS-45 NUH0VYxoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTBwMke4N|Mh|ryP MWDTRW5ITVJ?
DSH1 MoGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTBwMki3NFgh|ryP M4LSOnNCVkeHUh?=
HT-144 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrGTWxWUUN3ME2wMlMxOjV4IN88US=> NVPmeGNPW0GQR1XS
ATN-1 NVjuWYZKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXWR4JqUUN3ME2wMlMxPTd4IN88US=> M2e5S3NCVkeHUh?=
HEL MonHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvWXmN2UUN3ME2wMlMyOzR6IN88US=> Mn7HV2FPT0WU
NB12 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnzVpI5UUN3ME2wMlMyPzV4IN88US=> MoGzV2FPT0WU
LU-139 M1XMfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknLTWM2OD1yLkOzOVEh|ryP M4TjNXNCVkeHUh?=
J-RT3-T3-5 M3\HOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TEWWlEPTB;MD6zN|cyPiEQvF2= MmiwV2FPT0WU
MOLT-13 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrPR3d4UUN3ME2wMlM{QDFizszN NXvU[XZLW0GQR1XS
SR M3jpU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLjTWM2OD1yLkO0NlYyKM7:TR?= MnnOV2FPT0WU
CMK MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfGdW9OUUN3ME2wMlM2PzJ5IN88US=> NVO1N4hkW0GQR1XS
ES8 NGHaXYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTBwM{[wNlIh|ryP MWjTRW5ITVJ?
LB647-SCLC MmP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7rTWM2OD1yLkO2O|Mh|ryP Ml3RV2FPT0WU
TE-8 NF3SeZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHP2UpdKSzVyPUCuN|Y6OzVizszN M2fOZnNCVkeHUh?=
BV-173 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLMT2FIUUN3ME2wMlM4OTJzIN88US=> NFTyVGdUSU6JRWK=
DEL M{\aW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTxRXhKSzVyPUCuN|c1QDdizszN NYjWbGVSW0GQR1XS
ARH-77 MmLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTBwM{ixPVMh|ryP M1vnXnNCVkeHUh?=
NCCIT MmrHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPiTWM2OD1yLkO4OlQ6KM7:TR?= NXnxZ3Z4W0GQR1XS
RPMI-8402 MnvlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\GTWM2OD1yLkO4O|AyKM7:TR?= M3;5UnNCVkeHUh?=
MONO-MAC-6 NH:yRplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;pc2lEPTB;MD6zPFc4PiEQvF2= NXzFOpRrW0GQR1XS
SK-MM-2 M36yNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vWeGlEPTB;MD6zPVg3QCEQvF2= MmLJV2FPT0WU
CHP-126 MmnIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTBwNECyN|Eh|ryP MXvTRW5ITVJ?
A101D NXH2ZVFGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jqXmlEPTB;MD60NFMh|ryP M1z4OnNCVkeHUh?=
SCH M2\Hbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTaTWM2OD1yLkSwN|QzKM7:TR?= MojvV2FPT0WU
NMC-G1 Ml\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTBwNECzOlch|ryP NVPseJhvW0GQR1XS
NCI-H209 NVSzRlU1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfxTWM2OD1yLkSwOlE{KM7:TR?= MlP0V2FPT0WU
MOLT-16 M3Gw[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXRTWM2OD1yLkSxNFE4KM7:TR?= MoW2V2FPT0WU
RPMI-6666 M3vCTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjSTWM2OD1yLkSxNVIh|ryP MV7TRW5ITVJ?
OPM-2 MlqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTBwNEG1NVMh|ryP M4nPdXNCVkeHUh?=
MRK-nu-1 MlnNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPtNWtVUUN3ME2wMlQ{OTV|IN88US=> NH6zUFNUSU6JRWK=
BC-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXVTWM2OD1yLkSzOFA{KM7:TR?= MkTCV2FPT0WU
MHH-NB-11 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrafpdKSzVyPUCuOFM1PTNizszN M2\rXnNCVkeHUh?=
Ramos-2G6-4C10 NIDuU|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnDWZJnUUN3ME2wMlQ{QDl5IN88US=> NUP1dGs6W0GQR1XS
LS-513 NYfZR|JkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUWxN2l1UUN3ME2wMlQ1PTBzIN88US=> M{jodnNCVkeHUh?=
K5 M4nPWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4S5XmlEPTB;MD60O|AzPSEQvF2= M4njUXNCVkeHUh?=
HOP-62 NVn5[5UyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTBwNEizOVgh|ryP M4fFZnNCVkeHUh?=
NCI-H187 NH;Mb3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGKxZ5NKSzVyPUCuOFkzOjdizszN MVXTRW5ITVJ?
BE-13 MmTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLLTWM2OD1yLkS5OlYyKM7:TR?= MlLuV2FPT0WU
HC-1 NUjtXZVTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTBwNUC0O|Mh|ryP MXHTRW5ITVJ?
ACN MkPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzJPG82UUN3ME2wMlUyODJ6IN88US=> MYLTRW5ITVJ?
HCC1599 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnj3TWM2OD1yLkWxOVch|ryP NGXa[VZUSU6JRWK=
MV-4-11 MmT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTnWHJKSzVyPUCuOVMxPDFizszN NEjYNGRUSU6JRWK=
LC-2-ad NFm2U2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTBwNUO2OlMh|ryP M{n6NnNCVkeHUh?=
HL-60 NYHIVXo1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDJTWM2OD1yLkW0NlYyKM7:TR?= NXjVbIZQW0GQR1XS
NB17 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHwTWM2OD1yLkW0N|gh|ryP M2P1fnNCVkeHUh?=
TE-1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXztPGJTUUN3ME2wMlU2OzB4IN88US=> NGC4WoVUSU6JRWK=
NCI-H524 NUDvWnZQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHjcGRWUUN3ME2wMlU2PDBzIN88US=> NEP1cHFUSU6JRWK=
MZ7-mel MnruS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jpeGlEPTB;MD61OlExPSEQvF2= NGf6dIlUSU6JRWK=
L-363 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7mbpNDUUN3ME2wMlU3PjV5IN88US=> M{n3RXNCVkeHUh?=
BL-41 NVu1d3pkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTXTWM2OD1yLkW2PFg6KM7:TR?= MX3TRW5ITVJ?
LU-134-A MoXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTGTWM2OD1yLkW3NFc{KM7:TR?= NUfoPGNJW0GQR1XS
SIG-M5 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTBwNUe4OFgh|ryP M{XGWXNCVkeHUh?=
ONS-76 M3[zXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLNboJTUUN3ME2wMlU5OjR{IN88US=> M1rKOXNCVkeHUh?=
KARPAS-299 MnL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDITWM2OD1yLkW4OVA1KM7:TR?= M2jkRnNCVkeHUh?=
DU-4475 NH7FU2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLpOIpvUUN3ME2wMlU5PzB|IN88US=> NGKyWnNUSU6JRWK=
NB69 MofnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXYOmF1UUN3ME2wMlU6QDJ3IN88US=> NHyyVFBUSU6JRWK=
MHH-PREB-1 M1XmZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrQUY9KSzVyPUCuOlA4OTlizszN Mn7SV2FPT0WU
LU-165 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4[0UWlEPTB;MD62NVgyOiEQvF2= M{\NNnNCVkeHUh?=
LOUCY NETDV3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTBwNkOzOlQh|ryP M1XyenNCVkeHUh?=
NCI-H526 M{HXNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XnSmlEPTB;MD62N|U1OSEQvF2= MVnTRW5ITVJ?
KE-37 Mk\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTZO3J7UUN3ME2wMlY1Ojd4IN88US=> NFX1UVVUSU6JRWK=
NALM-6 M{[1WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vnU2lEPTB;MD62OFg3KM7:TR?= MVrTRW5ITVJ?
CW-2 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TMUWlEPTB;MD62OVc6PCEQvF2= MVLTRW5ITVJ?
SU-DHL-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHQWlNKSzVyPUCuOlU6PDdizszN MWHTRW5ITVJ?
NB13 NIjRVWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTBwNk[4NVch|ryP MX3TRW5ITVJ?
QIMR-WIL MkDqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zOU2lEPTB;MD62PFM1OyEQvF2= NH71WFRUSU6JRWK=
ECC12 MlPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDNRXNKSzVyPUCuO|AxQDZizszN M2e0XnNCVkeHUh?=
KALS-1 M2DQPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjhTpVKSzVyPUCuO|A1QTJizszN NWTVWZFbW0GQR1XS
COR-L279 NIHzUYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLmTWM2OD1yLkewPVk3KM7:TR?= NGO3SYVUSU6JRWK=
NB14 NIXaXIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknvTWM2OD1yLkeyOlE4KM7:TR?= MlG5V2FPT0WU
CCRF-CEM NUC1VI9vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfjWm06UUN3ME2wMlc1PjZzIN88US=> M4fXfHNCVkeHUh?=
SW954 Mlv6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\yZodqUUN3ME2wMlc2QTl7IN88US=> MmjNV2FPT0WU
IST-SL1 M3TvdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFP5c5BKSzVyPUCuO|c{PDhizszN Mn3aV2FPT0WU
LAMA-84 NF7OZYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\KXmlEPTB;MD63O|U3PyEQvF2= Mm[5V2FPT0WU
Daudi MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2f6b2lEPTB;MD63O|Y5OSEQvF2= M4HMR3NCVkeHUh?=
BC-3 MnTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTBwN{izNFgh|ryP MWHTRW5ITVJ?
HCC2998 NH3RZppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPkTWM2OD1yLke4N|Yh|ryP NIXLXYtUSU6JRWK=
NCI-H69 M3\xWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{H4NmlEPTB;MD64NFE1PyEQvF2= M3\NV3NCVkeHUh?=
CPC-N NWLxeoxjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrMTWM2OD1yLkiwOVI1KM7:TR?= MX3TRW5ITVJ?
NOMO-1 NFP4WHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnzOnZZUUN3ME2wMlgyODh2IN88US=> NYjPUXVrW0GQR1XS
CESS MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTpRYMxUUN3ME2wMlgyOTl5IN88US=> NGjZXGNUSU6JRWK=
LC4-1 Mlm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTBwOESwNFch|ryP MXzTRW5ITVJ?
BL-70 NInETpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NES2NYZKSzVyPUCuPFU4ODJizszN NHz2[|dUSU6JRWK=
ES4 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrGTWM2OD1yLki1PFY5KM7:TR?= M37SPXNCVkeHUh?=
HCE-T NUHQcIltT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTBwOEexO|Eh|ryP MlfFV2FPT0WU
JAR NU\wWVFoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nFR2lEPTB;MD64O|gzPyEQvF2= MYPTRW5ITVJ?
ST486 M13iOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fLOWlEPTB;MD64O|kyPyEQvF2= NFjRTItUSU6JRWK=
KS-1 NXS4Z2JJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLIR2NxUUN3ME2wMlg5ODl4IN88US=> NEPpd2JUSU6JRWK=
GDM-1 M3HldGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfXbG9KSzVyPUCuPFg3QDdizszN NVjBc3c3W0GQR1XS
EHEB NFjKem5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILDcVRKSzVyPUCuPVI2QDVizszN M{D0T3NCVkeHUh?=
LB2518-MEL MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTHTWM2OD1yLkmzNlg1KM7:TR?= MX\TRW5ITVJ?
GOTO MoCyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTBwOUWwO|Yh|ryP MlT6V2FPT0WU
LXF-289 M3HC[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTBwOUW5NFEh|ryP NEThenNUSU6JRWK=
ES6 MoPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnizTWM2OD1yLkm2OFM4KM7:TR?= MmDqV2FPT0WU
OS-RC-2 MmKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTBwOU[4N{DPxE1? MVfTRW5ITVJ?
DMS-153 NGfLN41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17qc2lEPTB;MD65O|Q3QSEQvF2= NYP3Spl2W0GQR1XS
SK-PN-DW M2rFWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXDTWM2OD1yLkm3PFMyKM7:TR?= M135TnNCVkeHUh?=
HH M1vGb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\VUWlEPTB;MD65PFk2QSEQvF2= M1HjOHNCVkeHUh?=
SH-4 M3TBdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGD3Ro9KSzVyPUGuNFI1OSEQvF2= MnLYV2FPT0WU
MOLT-4 Mk\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVr6dW9VUUN3ME2xMlA{PDV2IN88US=> MljSV2FPT0WU
TGW M3zQNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTFwMEe2O|Uh|ryP M4jlZnNCVkeHUh?=
L-540 NV;i[|FtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTFwMUC2NFQh|ryP M2ewSXNCVkeHUh?=
PF-382 NXjwbXJyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTFwMUG1NVMh|ryP NH\6fJNUSU6JRWK=
LC-1F M4DtUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;rWmlEPTB;MT6xNlAxPyEQvF2= NGW1fZJUSU6JRWK=
OVCAR-4 NGniWIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoD4TWM2OD1zLkGzNVY2KM7:TR?= NYTrU2VtW0GQR1XS
A4-Fuk M{fJNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTFwMUWzOlQh|ryP M2G0eXNCVkeHUh?=
HCC2218 NUjmVoh5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2P1OmlEPTB;MT6xOlY1OSEQvF2= M3\NOnNCVkeHUh?=
HAL-01 MkjsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLjN|BKSzVyPUGuNVY6PDNizszN M1PZb3NCVkeHUh?=
IST-MEL1 NFP5[IJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUm1R4FyUUN3ME2xMlE4PjV7IN88US=> Mnz4V2FPT0WU
NCI-H719 M1fOSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm[zTWM2OD1zLkG3PFk5KM7:TR?= MlH5V2FPT0WU
EVSA-T MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfHWXM{UUN3ME2xMlE5OTF2IN88US=> M1HtS3NCVkeHUh?=
SK-NEP-1 MmXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTFwMkCyOlYh|ryP Mn7FV2FPT0WU
OCUB-M MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHwNmlKSzVyPUGuNlE1QDlizszN NE\YV2NUSU6JRWK=
MEG-01 NVvYWXJVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG[2bZhKSzVyPUGuNlIyOThizszN NF3NNGdUSU6JRWK=
no-10 NWHOcHc2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXq[lRKSzVyPUGuNlMyOTJizszN MlTlV2FPT0WU
MHH-CALL-2 NX3jdnczT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknDTWM2OD1zLkK0O|IyKM7:TR?= NIfsWpZUSU6JRWK=
SK-N-DZ Ml\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXuVlZKSzVyPUGuNlQ4PzZizszN M2DXPXNCVkeHUh?=
SCLC-21H MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnJSGJKSzVyPUGuNlY1PzhizszN NYS2RlZ6W0GQR1XS
CTV-1 M1\UXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTFwMke0NlUh|ryP MoG4V2FPT0WU
NB1 NHj5PXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTFwMke3N|Ih|ryP MX\TRW5ITVJ?
NCI-H64 MmPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7kTWM2OD1zLkK4OFYzKM7:TR?= NEmxSolUSU6JRWK=
MDA-MB-134-VI NVnkeGU5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTFwMki1O|ch|ryP MUHTRW5ITVJ?
LB2241-RCC M2nRfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPmU5VKSzVyPUGuNlg3PjNizszN M4LFfXNCVkeHUh?=
8-MG-BA M3LCZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml24TWM2OD1zLkK4PFY3KM7:TR?= NVnlbph2W0GQR1XS
LP-1 NEO4NnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rWeWlEPTB;MT6yPVk1PyEQvF2= M1;iU3NCVkeHUh?=
LS-411N NX7JOppjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;RTWM2OD1zLkOwPVk5KM7:TR?= MYjTRW5ITVJ?
CAL-148 MmfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4G4b2lEPTB;MT6zNlU1OiEQvF2= NH\zbFJUSU6JRWK=
NCI-H2171 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIH6cJhKSzVyPUGuN|Q2ODJizszN MVfTRW5ITVJ?
JiyoyeP-2003 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{i0ZmlEPTB;MT6zOVM6KM7:TR?= M3n3cHNCVkeHUh?=
NCI-H2107 NIDHdlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTFwM{W4PFMh|ryP NV;ic49sW0GQR1XS
BB30-HNC MoTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrQR5dKSzVyPUGuN|g6PzhizszN MoPaV2FPT0WU
K-562 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfNN2JtUUN3ME2xMlM6OjF7IN88US=> NUT4d2pHW0GQR1XS
PSN1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTFwNEKyPFch|ryP MVfTRW5ITVJ?
HCC2157 MmrWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLhTWM2OD1zLkSyOlkyKM7:TR?= MkfTV2FPT0WU
SBC-1 NIH0WXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTVPZlKSzVyPUGuOFI4PDFizszN NETuN41USU6JRWK=
MC116 MnfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTFwNEO2NVUh|ryP MmD3V2FPT0WU
KARPAS-422 NHLFOmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvTNZpQUUN3ME2xMlQ2OzV6IN88US=> Ml7XV2FPT0WU
LB996-RCC M{flZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DyeWlEPTB;MT60O|ExOyEQvF2= MnzSV2FPT0WU
MSTO-211H MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonNTWM2OD1zLkS3PVg4KM7:TR?= MoPBV2FPT0WU
BT-474 MlvvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTFwNUG3OlQh|ryP M1vnUXNCVkeHUh?=
A388 M2O5dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fhb2lEPTB;MT61NVk1PSEQvF2= NUC0NIRmW0GQR1XS
SJSA-1 NILMe2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfTSY1wUUN3ME2xMlUzOjZizszN MVTTRW5ITVJ?
COLO-829 Mo\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTFwNUO1OlQh|ryP NVWyeVJ[W0GQR1XS
KM-H2 MomzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnT2TWM2OD1zLkW2Olch|ryP M1[4SHNCVkeHUh?=
GR-ST M{DpSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHqRmFKSzVyPUGuOVY5OiEQvF2= NHHRfotUSU6JRWK=
RPMI-8866 NVPF[mxMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDKTWM2OD1zLk[wNVQ1KM7:TR?= NVHnS4k5W0GQR1XS
KG-1 MnvaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIWyUY9KSzVyPUGuOlE6ODFizszN MXXTRW5ITVJ?
NCI-H82 NEXofZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmW1TWM2OD1zLk[zOFA3KM7:TR?= Mn7IV2FPT0WU
LB1047-RCC Mk\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rKN2lEPTB;MT62N|Q2QSEQvF2= NV;yc|lWW0GQR1XS
KM12 NGO5c3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTFwNkS3JO69VQ>? Ml;MV2FPT0WU
NB5 M3zrXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTFwNkW2O|ch|ryP Mm\qV2FPT0WU
HDLM-2 NHvjS5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvvdZhUUUN3ME2xMlY5OjhzIN88US=> M1WyTHNCVkeHUh?=
KU812 M2PBWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3GXmZKSzVyPUGuOlk3ODVizszN NYPKV|R[W0GQR1XS
DB NUTjcHZRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fJNmlEPTB;MT63NFM2OyEQvF2= Mn3GV2FPT0WU
HD-MY-Z Mom2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTFwN{WyN|Qh|ryP MoLtV2FPT0WU
KURAMOCHI NVf2NVNuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfvU2NKSzVyPUGuO|czODdizszN Mke1V2FPT0WU
ETK-1 NWrtZWZGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDIT2xKSzVyPUGuO|g5PzlizszN M4jqc3NCVkeHUh?=
SK-UT-1 M3e5[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHLTWM2OD1zLke5N|g5KM7:TR?= NF3MOWpUSU6JRWK=
HUTU-80 Mmm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\qOIFKSzVyPUGuO|k2ODhizszN NEXFRlRUSU6JRWK=
ES7 NInybVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnBcoRKSzVyPUGuPFA{ODJizszN MnnIV2FPT0WU
SW872 NILFSopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LtcGlEPTB;MT64NVM6PSEQvF2= MYXTRW5ITVJ?
TK10 NHvqV4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LiNGlEPTB;MT64N|ExQCEQvF2= Mly4V2FPT0WU
LB831-BLC M{TrRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEexSXVKSzVyPUGuPFM2PjNizszN NGe3[lVUSU6JRWK=
TE-9 M2SwSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3pTYJDUUN3ME2xMlg1PDJ{IN88US=> NFTWeWNUSU6JRWK=
MLMA MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmO0TWM2OD1zLki4NlM1KM7:TR?= NGLDbpFUSU6JRWK=
D-542MG NUfpd|ZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUftZVNRUUN3ME2xMlg6Ozd|IN88US=> NXu3T|c6W0GQR1XS
EW-16 NWDkR5BFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TE[mlEPTB;MT65NlczKM7:TR?= MX\TRW5ITVJ?
LOXIMVI MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVThdmRCUUN3ME2xMlk{OjhizszN MY\TRW5ITVJ?
GB-1 NVS3cIZRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vkbGlEPTB;MT65N|g3PiEQvF2= M1G4V3NCVkeHUh?=
IST-SL2 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vEXmlEPTB;Mj6wNFI3OiEQvF2= MYHTRW5ITVJ?
LAN-6 NFyxb4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGSzRYRKSzVyPUKuNFE6PjZizszN NYjZNJZsW0GQR1XS
NCI-H510A M33reGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7rVmpnUUN3ME2yMlA1PTB{IN88US=> MkXZV2FPT0WU
NCI-H1092 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7OfWZKSzVyPUKuNFUyOjRizszN NYXFZ2lKW0GQR1XS
HT NUnwdGpjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;yTWM2OD1{LkGwOFU1KM7:TR?= MorTV2FPT0WU
RL95-2 MmHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTJwMUG0PFIh|ryP NIe2WpFUSU6JRWK=
NCI-H1355 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1Pq[WlEPTB;Mj6xNVc6OiEQvF2= MWDTRW5ITVJ?
NCI-H720 M{j4bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jmRmlEPTB;Mj6xOlg4OyEQvF2= NITYbFVUSU6JRWK=
NCI-H1522 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTJwMkG3NlMh|ryP MVvTRW5ITVJ?
LB373-MEL-D NFrWTXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTJwMk[5NFIh|ryP M{PGdnNCVkeHUh?=
DG-75 NYH4e3JbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnFVploUUN3ME2yMlI4OTR6IN88US=> MUHTRW5ITVJ?
ML-2 NHfpOlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;WTWM2OD1{LkOyPFU2KM7:TR?= MV7TRW5ITVJ?
SF126 NFnPTlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljPTWM2OD1{LkOzNFk1KM7:TR?= MV7TRW5ITVJ?
MPP-89 MnzZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDlfVNKSzVyPUKuN|MyPDVizszN MoDHV2FPT0WU
NCI-H345 NUTDO5lnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\0Nm5KSzVyPUKuN|MzPzdizszN NVn4e|BnW0GQR1XS
LS-123 M4Hyemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTJwM{S5N|Yh|ryP NH;XWG9USU6JRWK=
NB10 M2nRSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTOOolpUUN3ME2yMlQyODl{IN88US=> NGCw[GNUSU6JRWK=
CGTH-W-1 NWG1Nm1lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXITWM2OD1{LkSyNlY4KM7:TR?= NVzkcohKW0GQR1XS
CP66-MEL NULnOGkxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17id2lEPTB;Mj60O|c4KM7:TR?= NUHIeYR7W0GQR1XS
L-428 M{DkPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTJwNEi1NlEh|ryP M1;SVHNCVkeHUh?=
DMS-79 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELDdVNKSzVyPUKuOVQyODNizszN MojDV2FPT0WU
NCI-H1882 NWHMZmE5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7NW|BKSzVyPUKuOlc2PjJizszN NXfQdm5WW0GQR1XS
KGN NWS5NYZnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fWOmlEPTB;Mj63Olg4PiEQvF2= MV3TRW5ITVJ?
EW-1 NGHLXYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PqTGlEPTB;Mj63O|A5OyEQvF2= MlO3V2FPT0WU
U-266 M{DFW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHRZXRyUUN3ME2yMlg1QDJ|IN88US=> MWLTRW5ITVJ?
COLO-320-HSR MoizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjOSYZKSzVyPUKuPFU3PDFizszN NHfqcVBUSU6JRWK=
KMOE-2 Ml;LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfDcoZKSzVyPUKuPFc4OTFizszN MVHTRW5ITVJ?
BB49-HNC NHfXVo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTJwOUK0PEDPxE1? M3;yOHNCVkeHUh?=
GI-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXObIZvUUN3ME2yMlkzQTV5IN88US=> NIDwdWxUSU6JRWK=
NCI-H1304 MkHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3S4bWlEPTB;Mz6wNFUyOSEQvF2= NUTLU2JxW0GQR1XS
NCI-H2227 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTNwMEKwO|kh|ryP MnnHV2FPT0WU
U-87-MG NX\nfGJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTNwMEO1NVMh|ryP NV7XR3cyW0GQR1XS
NCI-H747 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTNwMEWyNFYh|ryP MVTTRW5ITVJ?
CTB-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mkf6TWM2OD1|LkC1N|c3KM7:TR?= MnXRV2FPT0WU
RPMI-8226 MnexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HOWGlEPTB;Mz6xOFM4QCEQvF2= MV7TRW5ITVJ?
NCI-H2141 Ml;hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTNwMU[1OlYh|ryP MnzUV2FPT0WU
IST-MES1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LSdmlEPTB;Mz6xPFI4QSEQvF2= NYLHV3J1W0GQR1XS
TE-5 MkWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTNwMkGzOFIh|ryP Ml3qV2FPT0WU
UACC-257 M4DHUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTNS49KSzVyPUOuOFM3PTlizszN MkmzV2FPT0WU
SK-N-FI NYm5PVdrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHixfZBKSzVyPUOuOFUzOjdizszN MXjTRW5ITVJ?
MFH-ino M{\CPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4e3SmlEPTB;Mz60OlU5QSEQvF2= M{DwXXNCVkeHUh?=
SF268 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTNwNEixO|Qh|ryP MV;TRW5ITVJ?
TE-12 M2HDXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13m[GlEPTB;Mz61NVY6QSEQvF2= NWjQepJTW0GQR1XS
NB6 NGTCO5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUX2PJN6UUN3ME2zMlU2PTZ|IN88US=> Ml3KV2FPT0WU
DJM-1 NHnCc4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fmWWlEPTB;Mz61PVg6QSEQvF2= M3LEWHNCVkeHUh?=
MZ1-PC M37WPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\BZolKSzVyPUOuOlE3OjRizszN MXjTRW5ITVJ?
OCI-AML2 NUnhTG1XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTNwNkK2O|Eh|ryP MnH6V2FPT0WU
NCI-H1155 M3vLbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LYN2lEPTB;Mz63NFk1PyEQvF2= MWDTRW5ITVJ?
RKO MlvkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXz1TGlpUUN3ME2zMlc4OTh7IN88US=> NY\uRWJ4W0GQR1XS
ECC4 NW[1e4FHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\L[FFKSzVyPUOuPVcyQTVizszN Ml2yV2FPT0WU
BB65-RCC M2HySWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILhd3hKSzVyPUOuPVc2PDdizszN MXvTRW5ITVJ?
EB-3 NFj6XJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHN[2NKSzVyPUOuPVk3OzNizszN M{jIXXNCVkeHUh?=
SHP-77 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XZb2lEPTB;ND6wNFUzPCEQvF2= MVfTRW5ITVJ?
NCI-H2196 MojkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3T5RWlEPTB;ND6wOVYzPSEQvF2= Mmi3V2FPT0WU
GI-ME-N NGXyNotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLNTWM2OD12LkC2N|k6KM7:TR?= NX\nUXVmW0GQR1XS
MN-60 NEn0UmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDRTWM2OD12LkGwPFch|ryP MnvpV2FPT0WU
NCI-H1694 NYfzWoJpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37ySWlEPTB;ND6xN|QxPSEQvF2= M1LUOXNCVkeHUh?=
LU-65 M37jeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;CTWM2OD12LkG1N|MzKM7:TR?= M3\TZ3NCVkeHUh?=
NCI-H1436 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTRwMUizN|Mh|ryP NXXWNYRWW0GQR1XS
KINGS-1 M4HmVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnY[m1RUUN3ME20MlMyPDN{IN88US=> M3eySHNCVkeHUh?=
GT3TKB NWLaOoxqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrXTWM2OD12LkOzNlY5KM7:TR?= MnzjV2FPT0WU
Becker M37mbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3LTWM2OD12LkO3N|EzKM7:TR?= NXL5PJZ7W0GQR1XS
HCC1187 NXf1R3RZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTRwOEm2OVch|ryP MljsV2FPT0WU
D-502MG M1PtPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnHRWlKSzVyPUWuNFA1OTZizszN M1vsSnNCVkeHUh?=
VA-ES-BJ M1;yOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHTdYU3UUN3ME21MlE{Pzd6IN88US=> MnP5V2FPT0WU
NB7 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\mSZhuUUN3ME21MlE1OTF{IN88US=> NWnBZ2Z[W0GQR1XS
SW962 NULDRlFDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\qRmlEPTB;NT6zPFgyPCEQvF2= NFfhfVhUSU6JRWK=
no-11 MoHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVK5O49KUUN3ME21Mlc3OzR|IN88US=> M1[2ZXNCVkeHUh?=
KNS-81-FD MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\LdWlEPTB;NT65NFY6PCEQvF2= M{HtOnNCVkeHUh?=
COLO-684 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHGTWM2OD13Lkm5OFk1KM7:TR?= MmXSV2FPT0WU
D-263MG NH\wfYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLPTWM2OD14LkC4PFk2KM7:TR?= Ml;oV2FPT0WU
EW-24 M{LPV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXJTWM2OD14LkK4OVEh|ryP MlH6V2FPT0WU
TE-10 MlXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXNVFBKSzVyPU[uOFI3OjNizszN NFTnXmNUSU6JRWK=
EKVX M4D5[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{mzO2lEPTB;Nj60OlMzOSEQvF2= MnXQV2FPT0WU
NCI-H1648 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH:4PGpKSzVyPU[uOlc2PTdizszN NULxSYJqW0GQR1XS
LB771-HNC NV;qdXNoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXy0dJhRUUN3ME22MlkzOzBzIN88US=> MkXkV2FPT0WU
SK-MEL-1 NVLJfWNET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTrV3dKSzVyPUiuNVMyPjZizszN NWS0S2lSW0GQR1XS
COLO-668 MlT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPSTWM2OD16LkK3O|g3KM7:TR?= NXrIenVZW0GQR1XS
EW-12 NFP0S2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRThwNEC4NFMh|ryP NH\GemJUSU6JRWK=
A253 MkP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7hTWM2OD16Lki0OlYyKM7:TR?= M{\UZnNCVkeHUh?=
NCI-H2126 NX6wTFFDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;MO3JYUUN3ME24Mlg6OzF7IN88US=> M2Dkc3NCVkeHUh?=
Calu-6 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLCcHJQUUN3ME24Mlk6ODR{IN88US=> MojLV2FPT0WU
NCI-H23 NVHpdnJFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlmyTWM2OD17LkG3O|Q3KM7:TR?= MWXTRW5ITVJ?
WSU-NHL MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTlwN{e0O|gh|ryP NXrrZYJUW0GQR1XS
MMAC-SF MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rY[WlEPTB;OT65O|kxPCEQvF2= Ml7MV2FPT0WU
SK-LMS-1 NELxb2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjEPJI4UUN3ME2xNE4zQDN2IN88US=> NHKzdYRUSU6JRWK=
GCIY MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTFyLkW5NlQh|ryP MWjTRW5ITVJ?
TE-15 NFrpW4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTFzLk[wNFQh|ryP NXSx[JRKW0GQR1XS
EoL-1-cell MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojtTWM2OD1zMT63OlgzKM7:TR?= M2HZenNCVkeHUh?=
NCI-H2081 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXhTWM2OD1zMT63O|g3KM7:TR?= MVTTRW5ITVJ?
EW-3 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjwTWM2OD1zMj6yOFY{KM7:TR?= M4Hac3NCVkeHUh?=
CAS-1 MlfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zaPGlEPTB;MUKuN|Y{OSEQvF2= NH\5[GRUSU6JRWK=
C2BBe1 M4r0N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zaUWlEPTB;MUKuOlE{OSEQvF2= M{jOfHNCVkeHUh?=
D-247MG NVzJVHdzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnXSZpLUUN3ME2xNk44QTV{IN88US=> MnXtV2FPT0WU
NCI-SNU-5 Mn72S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;0O2JqUUN3ME2xNk45ODF|IN88US=> NEnkVHdUSU6JRWK=
LS-1034 M1;OU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfQZXpKSzVyPUG0MlM6PzVizszN MnPqV2FPT0WU
EW-18 NVm5UJR{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{P6[GlEPTB;MUSuOFQ5KM7:TR?= MYDTRW5ITVJ?
Raji Ml36S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVP3XYsxUUN3ME2xOE42ODR7IN88US=> MYrTRW5ITVJ?
D-283MED MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTF2Lk[yO|Eh|ryP NIHDVYZUSU6JRWK=
MZ2-MEL MoTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3Swd2lEPTB;MUSuPVY6PiEQvF2= NVztUVVWW0GQR1XS
NCI-SNU-16 Mn3SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfs[3VKSzVyPUG1MlQ3OzNizszN MVXTRW5ITVJ?
P30-OHK MnzrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XTRWlEPTB;MUeuO|g{OSEQvF2= NWHoT|NvW0GQR1XS
RXF393 NF;WS4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHm4RmtKSzVyPUG5MlAyQDZizszN NWf0RZV1W0GQR1XS
NCI-H1395 MnznS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDuTWM2OD1{MD62O|A{KM7:TR?= NGiyVZpUSU6JRWK=
U-698-M Mlz0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTJyLkewO|Uh|ryP M4KyS3NCVkeHUh?=
NCI-SNU-1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nUeWlEPTB;MkCuO|IzOyEQvF2= NIf4foJUSU6JRWK=
SW684 NXLSclI4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjvVIlKSzVyPUKxMlE4OTZizszN M{f1T3NCVkeHUh?=
NCI-H716 NF7Lfm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TOdmlEPTB;MkGuN|E2PCEQvF2= NVWyfYRKW0GQR1XS
JVM-2 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPv[VNKSzVyPUKxMlQyOzNizszN NVzaWopsW0GQR1XS
NCI-H1581 NVnSPFl6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUC0UIpCUUN3ME2yNk41OTR6IN88US=> M2TtN3NCVkeHUh?=
CA46 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLxTWM2OD1|MT62PVM3KM7:TR?= M4X2enNCVkeHUh?=
SNB75 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\qSmZIUUN3ME2zN{43PTB|IN88US=> NHj4dpZUSU6JRWK=
KNS-42 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPRfVNYUUN3ME2zOU46PjJ2IN88US=> M1fpe3NCVkeHUh?=
TUR NIq0NYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrCbYNKSzVyPUO2MlA2OjFizszN MlvxV2FPT0WU
REH MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTFTWM2OD1|Nz64NlEyKM7:TR?= MWDTRW5ITVJ?
EW-22 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\6TWM2OD12Mj6yPFg2KM7:TR?= M{H1eXNCVkeHUh?=
NCI-H446 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnf5TWM2OD12Mj63PFU{KM7:TR?= NYLEeVQzW0GQR1XS
ES3 M2rw[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPXV5pKSzVyPUSzMlE{OzlizszN MoXVV2FPT0WU
EW-11 M4XlfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTR2LkiyNVgh|ryP NGrWc|dUSU6JRWK=
RH-1 MnPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLvbXZ{UUN3ME20O{42QDF{IN88US=> NUO3VWtDW0GQR1XS

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

体内試験 MS-275 exhibits great antitumor activity against human tumor xenografts except HCT-15 at 49 mg/kg. [1] MS-275 demonstrates promising therapeutic potential in both solid and hematologic malignancies, as well as regulation of physiologic and aberrant gene expression. [4] MS-275, combination with IL-2, has great antitumor activity to renal cell carcinoma xenograft model, which due to decreased T regulatory cells and increased splenocytes. [5]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[6]

+ 展開

Standard HDAC Assays:

Rat liver enzyme is diluted 1:6 with HDAC buffer. Recombinant human HDACs are diluted 1:4 in HDAC buffer. For standard HDAC assays, 60 μL of HDAC buffer is mixed with 10 μL of diluted enzyme solution at 30 °C. The HDAC reaction is started by adding 30 μL substrate solution in HDAC buffer followed by 30 min of incubation at 30 °C. The reaction is stopped by adding 100 μL trypsin solutions (10 mg/ml trypsin in 50 mM Tris-HCl [pH 8.0], 100 mM NaCl, 2 μM TSA). After a 20 min incubation period at 30 °C, the release of AMC is monitored by measuring the fluorescence at 460 nm (λex = 390 nm). Fluorescence intensity is calibrated using free AMC. For standard time course experiments, 20 pmol of substrate is used in the initial 100 μL HDAC reaction. Km and Vmax values are determined by measuring the fluorescence AMC generated by enzymatic cleavage of 2–50 pmol of substrate. The experimental data are analyzed using a Hanes plot. The AMC signals are recorded against a blank with buffer and substrate but without the enzyme.
細胞試験:

[2]

+ 展開
  • 細胞株: A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 cells
  • 濃度: ~ 10 μM
  • 反応時間: 3 days
  • 実験の流れ:

    Cancer cells (5 × 103) are seeded into each well of 96-well plates and cultured with graded concentrations of MS-275 for 3 days. The cells are stained with 0.1 mg/mL neutral red for 1 hour in a CO2-incubator, and, after aspiration of the medium, OD540 of the neutral red solubilized with 50 μL of ethanol and 150 μL of 0.1 M Na2HPO4 is measured. The IC50 value is determined by plotting growth inhibition of the cells against the logarithm of the drug concentration.


    (参考用のみ)
動物試験:

[1]

+ 展開
  • 動物モデル: A2780, HT-29, HTC-15, KB-3-1, 4-1St, St-4, Capan-1 and Calu-3 cells are injected subcutaneously into the flank of nude mice.
  • 製剤: Dissolved with 0.05 N HCl, 0.1% Tween 80
  • 投薬量: 12.3, 24.5 and 49 mg/kg
  • 投与方法: Administered orally once daily 5 days per week for 4 weeks
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 75 mg/mL (199.25 mM)
Water Insoluble
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
2% DMSO+30% PEG 300+ddH2O
混合させたのち直ちに使用することを推奨します。
10mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 376.41
化学式

C21H20N4O3

CAS No. 209783-80-2
保管
in solvent
別名 SNDX-275

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03838042 Not yet recruiting CNS Tumor|Solid Tumor University Hospital Heidelberg|German Cancer Research Center March 2019 Phase 1|Phase 2
NCT03829930 Not yet recruiting Prostate Adenocarcinoma George Washington University March 1 2019 Phase 1
NCT03765229 Recruiting Melanoma UNC Lineberger Comprehensive Cancer Center|Syndax Pharmaceuticals Inc. March 2019 Phase 2
NCT03838042 Not yet recruiting CNS Tumor|Solid Tumor University Hospital Heidelberg|German Cancer Research Center March 2019 Phase 1|Phase 2
NCT03829930 Not yet recruiting Prostate Adenocarcinoma George Washington University March 1 2019 Phase 1
NCT03765229 Recruiting Melanoma UNC Lineberger Comprehensive Cancer Center|Syndax Pharmaceuticals Inc. March 2019 Phase 2

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    I would like to use Entinostat(Catalog No.S1053) for animal study. What is your recommendation for the solvent? What is the role of PEG 300 in this case? Can I use DMSO only and dilute it with PBS or HBSS?

  • 回答:

    2%DMSO/30%PEG/68%Water is recommended. PEG is an important polymer that helps with the solubility of hydrophobic drugs. If you use DMSO only and dilute it with PBS or HBSS, Entinostat will likely to precipitate out since it has very low solubility in water.

HDACシグナル伝達経路

HDAC Inhibitors with Unique Features

相関HDAC製品

Tags: Entinostat (MS-275)を買う | Entinostat (MS-275) ic50 | Entinostat (MS-275)供給者 | Entinostat (MS-275)を購入する | Entinostat (MS-275)費用 | Entinostat (MS-275)生産者 | オーダーEntinostat (MS-275) | Entinostat (MS-275)化学構造 | Entinostat (MS-275)分子量 | Entinostat (MS-275)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID